NORTHLAND

NORTHLAND

Language

NORTHLAND Wins Three Awards in the 5th Wabe New Third Board Year-End Selection

发布时间：2020-12-25

On December 24, 2020, the "5th Wabe New Third Board Leading Enterprises Annual Conference & Wabe Golden Stock Awards Ceremony," jointly hosted by Wabe.com and the Wabe New Third Board Research Institute, was successfully held at the Crowne Plaza Hotel You Tang in Beijing. This year's conference was themed "New Starting Point, New Journey, New Future," and focused on exploring new opportunities in the New Third Board under the integrated multi-level capital market, the investment logic behind the Select Tier, and how to prepare for a potential transfer to the main board. During the event, the winners of the "2020 Wabe New Third Board Year-End Selection" were announced, along with a grand awards ceremony. Our company was honored with the title of "2020 Outstanding Chairman of the New Third Board."

11

2020-12

NORTHLAND Selected for the "Top 100 Chinese Pharmaceutical Innovation Enterprises 2020" List

发布时间：2020-12-11

Recently, the 12th (2020) China Pharmaceutical Entrepreneurs, Scientists, and Investors Conference—hosted by the China Association of Pharmaceutical Enterprise Management, the China Association of Pharmaceutical Biotechnology, and the General Office of the Central Committee of the China National Democratic Construction Association—was held in Hangzhou. During the conference, the “Top 100 Chinese Pharmaceutical Innovation Enterprises 2020” list was released, and our company was successfully included on the list. In this “Top 100 Innovation” selection, a model was developed, data were collected and organized, and the assessment started from the current state of pharmaceutical innovation. Taking enterprises as the main body and data as the foundation, the evaluation covered three dimensions: innovation foundations, innovation processes, and innovation outcomes. Key metrics included the number of granted patents, the total number of patent citations, and clinical trials...

07

2020-12

The interim communication meeting for the Phase III clinical trial of recombinant human hepatocyte growth factor naked plasmid injection was successfully held.

发布时间：2020-12-07

On December 5-6, 2020, NORTHLAND organized a meeting for investigators involved in the Phase III clinical trial of recombinant human hepatocyte growth factor naked plasmid injection (NL003). The principal investigator (PI) of this project—Professor Liu Changwei from Peking Union Medical College Hospital—and researchers from some of the centers that have already initiated the study attended the meeting. The meeting was chaired by Mr. Han Chengquan, Vice President in charge of clinical affairs at the company, who provided an overview of the investigational drug and its R&D progress. Representatives from the company and the CRO project manager respectively presented updates on the overall progress of the Phase III clinical trial, shared efficacy data, and discussed issues encountered during the trial. Participants took turns sharing their respective center’s experiences with the trial and engaged in thorough discussions on patient recruitment.

26

2020-11

The first patient has successfully been enrolled in the Phase IIa clinical trial of “Recombinant Human Thymosin β4 for Injection.”

发布时间：2020-11-26

On November 23, 2020, the Phase IIa clinical trial for the company’s independently developed “Recombinant Human Thymosin β4 for Injection,” indicated for the treatment of ischemia-reperfusion injury (MIRI) caused by acute myocardial infarction, successfully completed enrollment of its first patient at Beijing Chaoyang Hospital, affiliated with Capital Medical University. This clinical trial, led by Fuwai Hospital of the Chinese Academy of Medical Sciences, is being conducted at five participating research centers. All centers had already commenced operations by the end of October and have now officially entered the screening and enrollment phase. The trial is expected to complete full enrollment by the end of July next year. Thymosin β4 is a small-molecule protein naturally present in the human body, possessing cardioprotective and reparative properties as well as anti-inflammatory effects.

24

2020-11

NORTHLAND officially entered the Select Tier today.

发布时间：2020-11-24

On November 24, 2020, the promotion ceremony for NORTHLAND to the Select Tier of the National Equities Exchange and Quotations (NEEQ) was held at the NEEQ headquarters. More than 50 guests, including leaders from the NEEQ, leaders from Haidian District, intermediary agencies, investment institutions, as well as the company’s directors, supervisors, senior management, shareholders, and the CITIC Securities project team, jointly witnessed NORTHLAND’s moment of ascending to the Select Tier. Among the attendees were Mr. Chen Yongmin and Mr. Jia Zhonglei, leaders from the NEEQ; Ms. Di Huiqing, Deputy District Mayor of the People's Government of Haidian District, Beijing; Ms. Ding Chaoxia, Deputy Director of the Haidian District Financial Services Office; Mr. Zhu Feng, Deputy Director of the Investment Banking Committee of CITIC Securities Co., Ltd.; and representatives from Beijing Zhongguancun Shangdi Biotechnology.

20

2020-11

NORTHLAND will officially list on the Select Tier on November 24.

发布时间：2020-11-20

On November 17, 2020, our company received the "Letter of Approval for the Listing of Beijing Northland Biotechnology Co., Ltd. on the Select Tier of the National SME Share Transfer System." Following review and approval by the National Equities Exchange and Quotations Company, our company's shares will be listed on the Select Tier of the National Equity Exchange System on November 24, 2020, and the trading method will be changed to continuous auction. Since the company officially launched its listing work on the Select Tier in March of this year, with guidance and sponsorship from Zhongtai Securities, we have smoothly completed the transition from the Basic Tier to the Innovation Tier and will officially advance to the Select Tier on the 24th. Throughout this process, we have received support and recognition from a wide range of investment institutions and investors.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

Follow Us

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

WeChat Mini Program

Web site

WeChat Official Account

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license

Powered by 300.cn  Privacy Policy